Fibroblast growth factor receptor-immunoglobulin fusion
US6656728B1 · kind B1 · utility
41Cited by
9References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 7, 2000 |
| Grant date | Dec 2, 2003 |
| Priority date | — |
| Expiry date | Feb 7, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compositions and methods for inhibiting cell proliferation, especially angiogenesis. The invention specifically relates to fusions of the extracellular domain of a fibroblast growth factor receptor (FGFR) with a heterologous oligomerization domain, such as that contained in an immunoglobulin, to provide potent FGFR antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.